Phase I - first stage of testing in humans (20-50 people)
Phase II - testing larger groups of people (20-300)
Phase III - randomized, controlled, multicenter trials (300-3,000)
Phase IV - also known as Post Marketing Surveillance, is ongoing surveillance of a vaccine or drug after it has been approved by Health Canada as safe and effective
There are many personal benefits to participating in this research, in addition to your valuable contribution to health research. The benefits and risks will be thoroughly discussed with you before any decisions are made. Contact information for each study is included in the descriptions below. Participation is entirely voluntary and you may withdraw from the trial at any time.
* * * * *
Healthy women at least 20 weeks pregnant
The purpose of this study is to see if the antibodies (protection) are transferred from mother to baby through the placenta in high enough levels to provide protection to the newborn baby if the mother receives whooping cough vaccine during the third trimester of pregnancy.
Study information [PDF]
Contact:
Darlene tel: 470-8931 email: darlene.baxendale@iwk.nshealth.ca
Pamela tel: 470-8948 email Pamela.macintyre@iwk.nshealth.ca
Healthy women 24 to 35 weeks pregnant
The purpose of this study is to see if the antibodies (protection) are transferred from mother to baby through the placenta in high enough levels to provide protection to the newborn baby if the mother receives Group B Streptococcus vaccine during the third trimester of pregnancy.
Study information [PDF]
Contact:
Darlene tel: 470-8931 email: darlene.baxendale@iwk.nshealth.ca
If you would like to be notified of future studies please send us an email at ccfv@iwk.nshealth.ca or call (902) 470-8931
Thank you for your interest!
